Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is a pan-European approach the way forward for health technology assessment?

This article was originally published in Clinica

Executive Summary

Health technology assessment (HTA) and its increased influence on healthcare payers' decision-making process has a potentially profound impact on medtech manufacturers. In this article, Dr Mark Charny of UK consultancy Translucency examines the different components of HTA in Europe and whether a pan-EU HTA system is viable, as well as the growing importance of evidence-based medicine to help define the most effective clinical care

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT099362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel